Generated by AI
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.
Website9920 Pacific Heights Boulevard
San Diego, CA, 92121
United States
The latest articles about VKTX.
Viking Therapeutics has delivered very strong long term share returns, and that kind of history can leave investors wondering whether the current US$28.44 price still lines up with what its balance sheet says the business is worth. With the spotlight on Viking Therapeutics as it pushes ahead in obesity drug development, the open question is how far the market price has moved relative to its book value. Over the past 5 years, Viking Therapeutics has returned about 391.2%, which raises the...
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
These drugmakers offer very different risk-reward profiles.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about VKTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.